ABIVAX (EPA:ABVX) | Finanzwire

Basculer en Français

8302	Companies
115121	Keywords
55446	Articles
62530	Press releases

Home
Companies
ABIVAX

BRIEF

published on 07/15/2024 at 22:05, 4 months 6 days ago

Abivax announces advances in its clinical program and updates its operations

Treasury Ulcerative Colitis Nomination Update Clinical Program
PRESS RELEASE

published on 07/15/2024 at 22:00, 4 months 6 days ago

Abivax Provides Operational and Key Program Update
Abivax provides operational and key program update, including progress on clinical trials, leadership changes, and financial update

Leadership Changes Abivax Clinical Trials Operational Update Financial Update
BRIEF

published on 06/28/2024 at 18:05, 4 months 23 days ago

ABIVAX: Summary of the Number of Shares and Voting Rights as of May 31, 2024

Voting Rights Actions AMF Abivax Transparency
BRIEF

published on 05/29/2024 at 18:05, 5 months 23 days ago

ABIVAX: Number of shares and voting rights as of April 30, 2024

Voting Rights Actions AMF Abivax Regulatory
BRIEF

published on 05/08/2024 at 08:35, 6 months 13 days ago

Presentation of Obefazimod for Ulcerative Colitis and Colon Cancer at DDW 2024

Abivax Obefazimod Ulcerative Colitis Digestive Disease Week Colon Cancer
PRESS RELEASE

published on 05/08/2024 at 08:31, 6 months 13 days ago

Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
Abivax presents four abstracts on obefazimod for ulcerative colitis and colon cancer model at Digestive Disease Week 2024. The company highlights novel mechanism of action and positive clinical data for obefazimod

Abivax Obefazimod Ulcerative Colitis Digestive Disease Week Colon Cancer
PRESS RELEASE

published on 05/08/2024 at 08:30, 6 months 13 days ago

Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024. The event will showcase new data on obefazimod's impact and mechanism of action

Abivax Obefazimod Ulcerative Colitis Colon Cancer Digestive Disease Week 2024
BRIEF

published on 05/07/2024 at 22:05, 6 months 14 days ago

Abivax Announces Availability of Documents for Upcoming General Meeting

Biotechnology Shareholder Information Corporate Governance Abivax General Meeting
PRESS RELEASE

published on 05/07/2024 at 22:00, 6 months 14 days ago

Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
Abivax informs shareholders of its ordinary and extraordinary general meeting on May 30, 2024, providing access to preparatory documents and details on participation. Obefazimod and Abivax information included

Abivax Obefazimod General Meeting Clinical-stage Biotechnology Preparatory Documents
PRESS RELEASE

published on 05/07/2024 at 22:00, 6 months 14 days ago

Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
Abivax announces its annual ordinary and extraordinary general meeting on May 30, 2024, with preparatory documents available for shareholders. The meeting details, including agenda and resolutions, are accessible on the company's website

Shareholders Biotechnology Abivax General Meeting Preparatory Documents

Accesswire

Published on 11/21/2024 at 22:05, 58 minutes ago

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 1 hour 13 minutes ago

Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 2 hours 48 minutes ago

Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 2 hours 53 minutes ago

For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform
Published on 11/21/2024 at 20:00, 3 hours 3 minutes ago

Victory for New York Homeowners: Petroff Amshen LLP Blocks Lender’s Repeated Foreclosure Attempt

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 19:01, 4 hours 2 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/21/2024 at 18:36, 4 hours 27 minutes ago

Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 5 hours 5 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 5 hours 12 minutes ago

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 5 hours 12 minutes ago

2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.

Les Echos

Published on 11/21/2024 at 06:58, 16 hours 5 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 3 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 5 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 5 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 15 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE